This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.This is a phase 1 safety study, where the primary objective is to determine the biodistribution of In-AHN-12 in patients with recurrent/refractory CD45+ lymphoma. Secondary objectives are to determine the maximum tolerated dose of Y-AHN-12, the human anti-mouse antibody (HAMA) response, and preliminarily define the antitumor activity of Y-AHN-12.
Showing the most recent 10 out of 724 publications